Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full Proposal)
Funding Amounts: Up to $3,000,000 total over 3 years per award; smaller budgets considered; indirect costs up to 10% for nonprofits.
Summary: Supports clinical trials to advance therapies aimed at improving cardiovascular outcomes in people with type 1 diabetes.
Key Information: Letter of Intent is required before full proposal submission.